Puerto Rico Can Puerto Rico capitalise on the Trump administration’s “make in America” push?   President Donald Trump wants to bring manufacturing back to America. The last 40 years of globalisation and free trade saw huge chunks of the US supply chain for all kinds of goods, including essential medicines and medical…

Puerto Rico With over 80,000 people directly and indirectly employed in Puerto Rico’s biosciences sector, the island relies heavily on a skilled and stable workforce to maintain its competitive edge. But it faces a tough talent landscape: the median age of the local workforce is rising, and post-hurricane migration, combined with global…

Mexico Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments and regulatory shake‑up as game-changing. But pharma leaders argue that real-world access remains elusive, with one industry veteran warning it…

Europe Pharma and biotech companies are doubling down on innovation and, often, outsourcing just about everything else. That shift has turned contract development and manufacturing organisations (CDMOs) into critical partners, not just service providers. The sector is booming, but pressure is building fast: demand is surging, capacity is stretched, and new…

UK The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and why AstraZeneca’s latest US manufacturing investment does little to ease fears that the British firm might choose to relocate across…

Puerto Rico Across over 50 interviews with Puerto Rican government and industry stakeholders, energy supply was continuously identified as the main barrier to growth. Puerto Rico’s ageing, centralised, and fossil fuel–dependent power system remains vulnerable to disruption from hurricanes and other natural events. However, new investments in renewables, battery storage, and decentralised…

Africa Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold, a consultant to the Gates Foundation, unveil the “Continental List of Human Medicinal Products” pilot—a first-of-its-kind initiative led by the…

Global Writing in the July 2025 edition of DIA Global Forum, Samantha Holmes, Fiona Adshead, and Keith Moore of the Sustainable Healthcare Coalition explore how cross-sector partnerships are advancing environmental sustainability in healthcare. They highlight real-world examples—from GSK’s Carbon Neutral Lab to the SMI Health Systems Task Force; showing how collaboration…

Global Alzheimer’s Disease takes a heavy toll; not just on patients and caregivers, but on society as a whole. As populations age, this complex and often-stigmatised condition is becoming harder to ignore. Despite recent breakthroughs, we are still far from having the right tools: better diagnostics, effective treatments, and smarter healthcare…

Denmark As clinical trials increasingly drift toward Asia and the US, can Denmark offer a blueprint for revitalising Europe’s competitive edge?   As Europe’s leader in clinical trials per capita, Denmark combines a deep domestic commitment to cutting-edge research with strong international confidence as a destination for investment. In 2023, the…

Denmark While Big Pharma giants chase blockbuster drugs across multiple therapeutic areas, three Danish mid-cap companies are pursuing a different path to survival. Facing mounting pressures and global competition, ALK, LEO Pharma, and Lundbeck have turned to fresh leadership and bold transformation strategies. Drawing on exclusive interviews with the three CEOs…

Switzerland In a milestone for global health, Novartis has received Swissmedic approval for Coartem Baby, the world’s first antimalarial treatment tailored for newborns and infants under 4.5kg. The decision fills a long-standing therapeutic gap and reinforces the company’s commitment to diseases that fall outside the pharmaceutical industry’s traditional commercial priorities.  …